Till is a serial founder and angel investor with over 20 years life science experience in biopharma, diagnostics, digital health, and med-tech. Founder of Myelo Therapeutics (sold to Eckert & Ziegler AG), Treamid Therapeutics (secondary exit), and IDrug. Hands-on experience in strategy development, general management and troubleshooting, fundraising, business development, and partnering. Over €40 Mio. venture capital and non-dilutive funding raised.

Prior to becoming a founder, Till worked in management consulting and subsequently in various strategy, marketing, and commercial roles at Bayer Pharma and Thermo Fisher Scientific. He is an engineer and MBA by training.